DXCM STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into DexCom, Inc. and Encourages Investors to Contact the Firm Today!
NEW YORK CITY, NY / ACCESSWIRE / August 11, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of DexCom, Inc. ("DexCom" or "the Company") (NASDAQ:DXCM). Investors who purchased DexCom securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/DXCM.
DXCM INVESTOR NOTICE: DexCom, Inc. is being Investigated for Securities Fraud; Investors with Losses are Encouraged to Contact BFA Law about a Potential Class Action
NEW YORK, NY / ACCESSWIRE / August 11, 2024 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into DexCom, Inc. (NASDAQ:DXCM) for potential violations of the federal securities laws. If you invested in DexCom, you are encouraged to obtain additional information by visiting Click Here
Investors Can Participate In The DexCom Inc Securities Fraud Investigation With The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / August 9, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of DexCom, Inc. ("DexCom" or "the Company") (NASDAQ: DXCM ) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
DexCom Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages DexCom, Inc. (NASDAQ: DXCM) Investors with Significant Losses to Contact the Firm
RADNOR, PA / ACCESSWIRE / August 9, 2024 / The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of DexCom, Inc. (NASDAQ:DXCM) ("DexCom"). On July 25, 2024, after the market closed, DexCom announced disappointing earnings results for its second quarter of 2024 and slashed full year revenue guidance from $4.35 billion to $4 billion-$4.05 billion.
DXCM SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into DexCom, Inc. and Encourages Investors to Contact the Firm Today!
NEW YORK CITY, NY / ACCESSWIRE / August 9, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of DexCom, Inc. ("DexCom" or "the Company") (NASDAQ:DXCM). Investors who purchased DexCom securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/DXCM.
DXCM INVESTIGATION UPDATE: DexCom, Inc. Investors with Losses on their Investment are Notified of Securities Fraud Investigation; Contact BFA Law for Details (Nasdaq:DXCM)
NEW YORK, NY / ACCESSWIRE / August 9, 2024 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into DexCom, Inc. (NASDAQ:DXCM) for potential violations of the federal securities laws. If you invested in DexCom, you are encouraged to obtain additional information by visiting Click Here
Investors Can Participate In The DexCom Inc Securities Fraud Investigation With The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / August 8, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of DexCom, Inc. ("DexCom" or "the Company") (NASDAQ: DXCM ) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Should You Buy DexCom Stock After Its Post-Earnings Sell-Off?
DexCom's growth rate has been declining over multiple periods. The company expects as little as 1% organic growth for the current quarter.
DXCM INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into DexCom, Inc. and Encourages Investors to Contact the Firm Today!
NEW YORK CITY, NY / ACCESSWIRE / August 8, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of DexCom, Inc. ("DexCom" or "the Company") (NASDAQ:DXCM). Investors who purchased DexCom securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/DXCM.
DXCM Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages DexCom, Inc. (NASDAQ: DXCM) Investors with Significant Losses to Contact the Firm
RADNOR, PA / ACCESSWIRE / August 8, 2024 / The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of DexCom, Inc. (NASDAQ:DXCM) ("DexCom"). On July 25, 2024, after the market closed, DexCom announced disappointing earnings results for its second quarter of 2024 and slashed full year revenue guidance from $4.35 billion to $4 billion-$4.05 billion.
DexCom's Competitive Landscape: A Deep Dive Into The CGM Market
DexCom, Inc. reduced its 2024 revenue guidance following a decline in new U.S. customers and revenue per customer, leading to a sharp share price drop and a $750 million share repurchase. DexCom faces strong competition from Abbott, whose CGM devices appear more attractive to customers, particularly with the new Abbott-Medtronic partnership posing a significant challenge to DexCom's market share recovery efforts. Despite competitive concerns, DexCom's new OTC CGM device, Stelo, is expected to contribute to revenue growth, particularly as the OTC market is projected to reach $5.1 billion over the next.
These Stocks Just Dropped by 40% and 15% -- Should You Buy the Dip?
DexCom and Pinterest delivered decent second-quarter results. However, their third-quarter projections were much less impressive.
